GGrantIndex
← Leaderboards

Steven Roth

University Of Chicago

$7,696,385
Attributed
$8,698,438
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $866.6K · FY200625
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,698,438 · 5

By mechanism

R01$7,733,341 · 3
R21$965,097 · 2

Top collaborators

Most similar at University Of Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Blindness

Research focus

BlindnessRetinaInnovationPreventIschemiaIn VivoNeuroprotectionHypoxiaRetinal IschemiaRetinal DiseasesApoptosisInjuryPathway InteractionsDiabetic RetinopathyInflammationRetinal Ganglion CellsCellsCell DeathExtracellular VesiclesMolecularEventEngineeringInflammatoryAttenuated

Grant awards (30)

Mesenchymal stem cell extracellular vesicles for ischemic retinal damage$449,165
R01 · FY2025 · EY · contact PI
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage$480,304
R01 · FY2024 · EY · contact PI
VRC: Engineered extracellular vesicles for mild TBI-induced retinal injury$312,420
R01 · FY2024 · EY · contact PI
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage$34,369
R01 · FY2024 · EY · contact PI
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage$480,304
R01 · FY2023 · EY · contact PI
VRC: Engineered extracellular vesicles for mild TBI-induced retinal injury$317,596
R01 · FY2023 · EY · contact PI
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage$51,555
R01 · FY2023 · EY · contact PI
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage$17,186
R01 · FY2023 · EY · contact PI
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage$491,224
R01 · FY2022 · EY · contact PI
VRC: Engineered extracellular vesicles for mild TBI-induced retinal injury$337,600
R01 · FY2022 · EY · contact PI
Novel Cell Free Therapy for Glaucoma$249,661
R21 · FY2020 · EY · contact PI
Novel Cell Free Therapy for Glaucoma$32,375
R21 · FY2020 · EY · contact PI
Novel Cell Free Therapy for Glaucoma$195,009
R21 · FY2019 · EY · contact PI
Risk factor anaylysis of perioperative visual loss$211,122
R21 · FY2018 · EY · contact PI
Risk factor anaylysis of perioperative visual loss$25,012
R21 · FY2018 · EY · contact PI
Risk factor anaylysis of perioperative visual loss$251,918
R21 · FY2017 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$382,200
R01 · FY2014 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$370,500
R01 · FY2013 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$390,000
R01 · FY2012 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$368,896
R01 · FY2010 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$372,621
R01 · FY2009 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$174,174
R01 · FY2009 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$365,169
R01 · FY2008 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$372,621
R01 · FY2007 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$382,917
R01 · FY2006 · EY · contact PI
The Role of Adenosine in Retinal Ischemia$381,250
R01 · FY2004 · EY
The Role of Adenosine in Retinal Ischemia$381,250
R01 · FY2003 · EY
The Role of Adenosine in Retinal Ischemia$365,500
R01 · FY2002 · EY
ADENOSINE AND RETINAL ISCHEMIA$200,034
R01 · FY2001 · EY
ADENOSINE AND RETINAL ISCHEMIA$254,486
R01 · FY2000 · EY